BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8245 related articles for article (PubMed ID: 12662126)

  • 21. Aggressive lymphoma: improving treatment outcome with rituximab.
    Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
    Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rituximab].
    Okamoto R; Maeda Y; Sasaki T
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical use of rituximab in haematological malignancies.
    Avivi I; Robinson S; Goldstone A
    Br J Cancer; 2003 Oct; 89(8):1389-94. PubMed ID: 14562003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab in chronic lymphocytic leukemia.
    Montserrat E
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):34-9. PubMed ID: 12652463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
    J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab: an innovative therapy for non-Hodgkin's lymphoma.
    Wood AM
    Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):18-22. PubMed ID: 12040530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
    Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
    Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 413.